impact factor, citescore
logo
In press
In Press
Recent issue
Recent issue
Recent Supplement
Recent supplement
archives
Archives
articles free
Free to view
Search
Search
 

Full Papers

 

Psoriatic arthritis treated by anti-TNFs: a monocentric trial of 102 cases in Auvergne, France

1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11

 

  1. Department of Rheumatology, CHU Hôpital Gabriel Montpied, Clermont-Ferrand, France. msoubrier@chu-clermontferrand.fr
  2. Biostatistics and Research Department (DRCI), CHU Hôpital Gabriel Montpied, Clermont-Ferrand, France.
  3. Department of Rheumatology, CHU Hôpital Gabriel Montpied, Clermont-Ferrand, France.
  4. Department of Rheumatology, CHU Hôpital Gabriel Montpied, Clermont-Ferrand, France.
  5. Department of Rheumatology, CHU Hôpital Gabriel Montpied, Clermont-Ferrand, France.
  6. Department of Rheumatology, CHU Hôpital Gabriel Montpied, Clermont-Ferrand, France.
  7. Department of Rheumatology, CHU Hôpital Gabriel Montpied, Clermont-Ferrand, France.
  8. Department of Rheumatology, CHU Hôpital Gabriel Montpied, Clermont-Ferrand, France.
  9. Department of Rheumatology, CHU Hôpital Gabriel Montpied, Clermont-Ferrand, France.
  10. Department of Rheumatology, CHU Hôpital Gabriel Montpied, Clermont-Ferrand, France.
  11. Department of Rheumatology, CHU Hôpital Gabriel Montpied, Clermont-Ferrand, France.

CER9345
2016 Vol.34, N°6
PI 1059, PF 1064
Full Papers

Free to view
(click on article PDF icon to read the article)

PMID: 27607233 [PubMed]

Received: 15/02/2016
Accepted : 26/05/2016
In Press: 31/08/2016
Published: 28/11/2016

Abstract

OBJECTIVES:
While several registries have already evaluated the retention of anti-TNF therapy in psoriatic arthritis (PsA), they sometimes reach divergent conclusions. Our study therefore sought to assess therapeutic retention rates and predictive factors of response in a patient cohort from Auvergne, France, followed up in routine clinical practice.
METHODS:
Medical records of all PsA patients treated from 2002 to May 2015 were analysed. PsA diagnosis was established based on the CASPAR criteria.
RESULTS:
In total, 102 patients were analysed, comprising 62 men (44.6±12.6 years) and 40 women (37.8±13.4). Mean PsA evolution was 2.7 years (0.8–11.2). The most common forms were peripheral (47/102, 45.1%) and mixed (46/102, 46.1%) PsA. The anti-TNF treatment initiated was etanercept in 47 cases (45.2%), adalimumab in 29 (27.9%), infliximab in 20 (19.2%), and golimumab in six [5.8%]. In 28 cases (27.4%), anti-TNF was associated with methotrexate (MTX). Overall, the median duration of anti-TNF retention was 76.5 months. The hazard ratios (HR) for treatment cessation did not significantly differ between the etanercept and monoclonal antibody groups (HR=1.35[0.96–1.93], p=0.08). After 5 years, approximately 30.8% of etanercept patients and 68.8% of monoclonal antibody patients (adalimumab 71.2%; infliximab 67.2%) were still being treated. Combining with MTX did not prolong the overall retention rate (HR=0.85[0.37–1.96], p=0.71). Tobacco use was predictive of discontinuation (p=0.03).
CONCLUSIONS:
Our study demonstrates good anti-TNF treatment retention in PsA patients, as well as confirming the deleterious effect of smoking while providing no argument in favour of combined treatment with MTX to improve maintenance.

Rheumatology Article